JP2013543840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543840A5 JP2013543840A5 JP2013534404A JP2013534404A JP2013543840A5 JP 2013543840 A5 JP2013543840 A5 JP 2013543840A5 JP 2013534404 A JP2013534404 A JP 2013534404A JP 2013534404 A JP2013534404 A JP 2013534404A JP 2013543840 A5 JP2013543840 A5 JP 2013543840A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- nitrogen
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- -1 carbonylamino, aminocarbonyl Chemical group 0.000 claims 10
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000001931 aliphatic group Chemical group 0.000 claims 9
- 125000002877 alkyl aryl group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 6
- 150000001540 azides Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000524 functional group Chemical group 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical group NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 125000000746 allylic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 201000005569 Gout Diseases 0.000 claims 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018501 Lymphatic disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000013058 Weber syndrome Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 201000007293 brain stem infarction Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000009390 immune abnormality Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000006492 vascular dysfunction Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40588210P | 2010-10-22 | 2010-10-22 | |
| US61/405,882 | 2010-10-22 | ||
| PCT/IB2011/002796 WO2012052843A1 (en) | 2010-10-22 | 2011-10-24 | Pochoxime conjugates useful for the treatment of hsp90 related pathologies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016177446A Division JP2017039730A (ja) | 2010-10-22 | 2016-09-12 | Ｈｓｐ９０関連病態の治療のために有用なポコキシム複合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013543840A JP2013543840A (ja) | 2013-12-09 |
| JP2013543840A5 true JP2013543840A5 (enExample) | 2014-11-27 |
Family
ID=45350425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013534404A Pending JP2013543840A (ja) | 2010-10-22 | 2011-10-24 | Ｈｓｐ９０関連病態の治療のために有用なポコキシム複合物 |
| JP2016177446A Pending JP2017039730A (ja) | 2010-10-22 | 2016-09-12 | Ｈｓｐ９０関連病態の治療のために有用なポコキシム複合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016177446A Pending JP2017039730A (ja) | 2010-10-22 | 2016-09-12 | Ｈｓｐ９０関連病態の治療のために有用なポコキシム複合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140031302A1 (enExample) |
| EP (1) | EP2630132A1 (enExample) |
| JP (2) | JP2013543840A (enExample) |
| KR (1) | KR20140021520A (enExample) |
| CN (2) | CN103370311A (enExample) |
| AU (1) | AU2011319685B2 (enExample) |
| BR (1) | BR112013009614A2 (enExample) |
| CA (1) | CA2812320A1 (enExample) |
| IL (1) | IL225371A0 (enExample) |
| RU (1) | RU2013122898A (enExample) |
| WO (1) | WO2012052843A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP3738594A1 (en) | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics having an hsp90 ligand as binding moiety |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP3099332A4 (en) | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| JP6576942B6 (ja) | 2014-03-03 | 2019-11-27 | マドリガル ファーマシューティカルズ インコーポレイテッド | 標的治療薬 |
| MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| PL3292116T3 (pl) | 2015-02-02 | 2022-02-21 | Valo Health, Inc. | 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸 |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| KR20200016874A (ko) | 2017-06-20 | 2020-02-17 | 마드리갈 파마슈티칼스 인코포레이티드 | 표적화 치료제를 포함하는 병용 요법 |
| CA3067572A1 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2022082108A1 (en) * | 2020-10-16 | 2022-04-21 | The Brigham And Women's Hospital, Inc. | Compositions for inducing tumor immunity and reducing drug tolerance |
| CN119424412A (zh) * | 2024-12-04 | 2025-02-14 | 中国药科大学 | 以prdx1作为药物靶标的天然抑制剂在制备抗乳腺癌药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861156A (en) * | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| AU722492B2 (en) * | 1996-08-30 | 2000-08-03 | University Of Hawaii | Pharmaceutical compounds |
| WO1998025934A1 (en) * | 1996-12-13 | 1998-06-18 | Kyowa Hakko Kogyo Co., Ltd. | Dc 107 derivatives (2) |
| AU2001271567A1 (en) | 2000-06-29 | 2002-01-14 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| ITRM20010079A1 (it) * | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| TWI381852B (zh) * | 2005-09-27 | 2013-01-11 | Sigma Tau Ind Farmaceuti | 生物素二胺基衍生物類及其與大環螯合劑之共軛物 |
| US8329683B2 (en) * | 2006-06-02 | 2012-12-11 | Nexgenix Pharmaceuticals, Llc | Treatment of neurofibromatosis with radicicol and its derivatives |
| JP5465006B2 (ja) * | 2006-08-11 | 2014-04-09 | ユニベルシテ・ドウ・ストラスブール | キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物 |
| KR101835252B1 (ko) * | 2008-01-15 | 2018-03-06 | 유니베르시떼 드 스트라스부르 | 치료제로서 유용한 레조르실산 락톤의 합성 |
| CN102015673B (zh) * | 2008-02-21 | 2014-10-29 | 昂科协同公司 | 用作治疗剂的大环前药化合物 |
-
2011
- 2011-10-24 US US13/880,878 patent/US20140031302A1/en not_active Abandoned
- 2011-10-24 AU AU2011319685A patent/AU2011319685B2/en not_active Ceased
- 2011-10-24 CN CN2011800601830A patent/CN103370311A/zh active Pending
- 2011-10-24 RU RU2013122898/04A patent/RU2013122898A/ru unknown
- 2011-10-24 CN CN201611152551.5A patent/CN107011311A/zh active Pending
- 2011-10-24 JP JP2013534404A patent/JP2013543840A/ja active Pending
- 2011-10-24 CA CA2812320A patent/CA2812320A1/en not_active Abandoned
- 2011-10-24 EP EP11797116.8A patent/EP2630132A1/en not_active Withdrawn
- 2011-10-24 KR KR1020137012551A patent/KR20140021520A/ko not_active Ceased
- 2011-10-24 WO PCT/IB2011/002796 patent/WO2012052843A1/en not_active Ceased
- 2011-10-24 BR BR112013009614A patent/BR112013009614A2/pt not_active IP Right Cessation
-
2013
- 2013-03-20 IL IL225371A patent/IL225371A0/en unknown
-
2015
- 2015-02-02 US US14/611,978 patent/US20150374680A1/en not_active Abandoned
-
2016
- 2016-08-29 US US15/250,742 patent/US20170174669A1/en not_active Abandoned
- 2016-09-12 JP JP2016177446A patent/JP2017039730A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543840A5 (enExample) | ||
| CN111971279B (zh) | 趋化因子受体调节剂及其用途 | |
| JP6861703B2 (ja) | Ｔｇｒ５修飾物質およびその使用方法 | |
| NL1031741C2 (nl) | Purinederivaten. | |
| ES2777626T3 (es) | Sulfonilureas y compuestos relacionados y uso de los mismos | |
| JP2024059874A (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| ES2804101T3 (es) | Compuestos de 4-amino-imidazoquinolina | |
| ES2883298T3 (es) | Síntesis de indazoles | |
| ES2848648T3 (es) | Imidazoquinolinas pegiladas como agonistas de TLR7 y TLR8 | |
| JP2020530452A (ja) | 大員環免疫調節剤 | |
| WO2018196823A1 (en) | 2-amino-quinoline derivatives | |
| ES2801800T3 (es) | Síntesis de indazoles | |
| RU2013122898A (ru) | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью | |
| JP2022508719A (ja) | ガレクチンのガラクトシド阻害剤のプロドラッグ | |
| CA3241488A1 (en) | Ionizable amine lipids and lipid nanoparticles | |
| WO2018181428A1 (ja) | 核酸医薬及び多分岐脂質の複合体 | |
| WO2013044811A1 (zh) | 吉西他滨酰胺衍生物及其制备方法和用途 | |
| JP2024530031A (ja) | ヒトインターロイキン－２とポリエチレングリコールのコンジュゲート及びその使用 | |
| US12030861B1 (en) | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | |
| ES3028099T3 (en) | Polymorphic carbazole derivatives and uses thereof | |
| ES2991171T3 (es) | Profármacos en la modulación de la interleucina | |
| WO2018094227A1 (en) | Alkyl pyrrolopyrimidine analogs and methods of making and using same | |
| CA3145908A1 (en) | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer | |
| CN104587487B (zh) | 一种应用于靶向给药系统的新的支链连接体 | |
| US10538500B2 (en) | Tricyclic prodrugs |